Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shin Nippon Biomedical Laboratories reported a 5.3% increase in revenue for the six months ending September 2024, reaching 12,508 million yen, despite a significant drop in operating profit by 96.6%. The company’s net assets grew to 36,453 million yen, although the equity ratio decreased to 40.9%. Dividends for the fiscal year are forecasted to remain stable at 50 yen per share.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.